Kenya - English - Pharmacy and Poisons Board

skant healthcare ltd 1802-1805, gidc, phase iii, vapi – 396195, - artemether and lumefantrine - powder for oral suspension - artemether 180mg and lumefantrine 1080 mg - artemether and lumefantrine

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - artemether, quantity: 20 mg; lumefantrine, quantity: 120 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; crospovidone; saccharin sodium; hypromellose; magnesium stearate; polysorbate 80; colloidal anhydrous silica; flavour - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet dispersible tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in children and infants weighing between 5kg and less than 35kg.

Kenya - English - Pharmacy and Poisons Board

signature healthcare ltd p.o box 66172-00800 - artemether & lumefantrine - syrup - artemether 180mg & lumefantrine 1080mg - antimalarial antiprotozoals: combinations of

Kenya - English - Pharmacy and Poisons Board

dafra pharma gmbh weidboden 2714618 boningenswitzerland - artemether lumefantrine - powder for oral solution - 180 mg artemether / 1080 mg lumefantrine & 360 mg… - antimalarial antiprotozoals: combinations of

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artemether ph.int. and lumefantrine - tablet - each uncoated tablet contains: artemether… - artemether and lumefantrine

Uganda - English - National Drug Authority

dafra pharma ltd - beta artemether + lumefantrine - oral liquid ordinary dry suspensions/syrups/drops - 180 mg/60ml + 1080 mg/60ml

Zimbabwe - English - Medicines Control Authority

ipca laboratories ltd - artemether; lumefantrine - tablet; oral - 20; 120 mg

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artemether and lumefantrine tablets 20/120mg - tablet - artemether ph int - 20mg, lumefantrine 120mg - antimalarial antiprotozoals: combinations of

Kenya - English - Pharmacy and Poisons Board

ajanta pharma limited ajanta house charkop kandivli (west) mumbai 400 - artemether and lumefantrine - powder for oral suspension - artemether ph. int 180 mg lumefantrine 1080 mg - antimalarial antiprotozoals: combinations of

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - artemether (unii: c7d6t3h22j) (artemether - unii:c7d6t3h22j), lumefantrine (unii: f38r0jr742) (lumefantrine - unii:f38r0jr742) - artemether 20 mg - coartem tablets are indicated for treatment of acute, uncomplicated malaria infections due to plasmodium falciparum (p. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. coartem tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see clinical studies (14.1) ]. limitations of use: - coartem tablets are not approved for patients with severe or complicated p. falciparum malaria. - coartem tablets are not approved for the prevention of malaria. hypersensitivity known hypersensitivity to artemether, lumefantrine, or to any of the excipients of coartem tablets [see adverse reactions (6.2)] . strong cyp3a4 inducers coadministration of strong inducers of cyp3a4 such as rifampin, carbamazepine, phenytoin, and st. john’s wort with coartem tablets can result in decreased concentrations of artemether and/or lumefantrine and loss of antimalarial efficacy [see warnings and precautions (5.3), drug interactions (7.1), and cl